XML 44 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition (Details)
$ in Thousands
1 Months Ended 3 Months Ended
Oct. 31, 2020
USD ($)
Segment
Mar. 31, 2021
USD ($)
distributor
Mar. 31, 2020
USD ($)
distributor
Dec. 31, 2020
USD ($)
Disaggregation of Revenue [Line Items]        
Provisions for revenue reserves to reduce product revenues to product revenues, net   $ 50,800 $ 43,600  
Deferred revenue, non-current   $ 51,605   $ 50,858
Collaborative Arrangement        
Disaggregation of Revenue [Line Items]        
Upfront payment receivable $ 50,000      
Contingent payments receivable upon achievement of development and regulatory milestones (up to) 39,000      
Contingent payments receivable upon achievement of commercial milestones (up to) $ 60,000      
Royalty percentage (in excess of) 25.00%      
Company's share of clinical trial costs, percentage 50.00%      
Collaborative agreement expiration, period after first commercial sale of product 12 years      
Collaborative agreement, termination by counterparty, effective after written notice period | Segment 180      
Repayment of upfront payment upon termination, percentage 85.00%      
Reimbursement of development expenses upon termination, percentage 50.00%      
Customer Concentration Risk | Sales Revenue, Net | Rhopressa and Rocklatan        
Disaggregation of Revenue [Line Items]        
Number of distributors | distributor   3 3  
Customer Concentration Risk | Sales Revenue, Net | Rhopressa and Rocklatan | Distributor One        
Disaggregation of Revenue [Line Items]        
Concentration risk percentage   36.00% 37.00%  
Customer Concentration Risk | Sales Revenue, Net | Rhopressa and Rocklatan | Distributor Two        
Disaggregation of Revenue [Line Items]        
Concentration risk percentage   30.00% 33.00%  
Customer Concentration Risk | Sales Revenue, Net | Rhopressa and Rocklatan | Distributor Three        
Disaggregation of Revenue [Line Items]        
Concentration risk percentage   33.00% 28.00%